NCSTN
ENSG00000162736
Target class
Enzyme
Chromosome
1
Approved drugs
2
Clinical candidates (approved and in development)
7
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 7
- Chemical probe available
- No
- Target name
- NCSTN
- Gene name
- Nicastrin
- Gene symbol
- NCSTN
- Protein name
- Nicastrin
- KIAA0253
- APH2
- Gene biotype
- Protein coding
- Gene family
- Gamma-secretase complex subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 123.9
- Tissue specificity (Gini)
- 0.237
- Tissue specificity (tau)
- 0.638
- KEGG gene identifiers
- hsa:23385
- Protein interaction confidence
- 0.889333
- Protein interaction partners
- 21
- R-HSA-1251985
- R-HSA-1474228
- R-HSA-193692
- R-HSA-205043
- R-HSA-2122948
- R-HSA-2644606
- R-HSA-2894862
- R-HSA-2979096
- R-HSA-3928665
- R-HSA-6798695
- R-HSA-9013507
- R-HSA-9013700
- R-HSA-9017802
- R-HSA-977225
- R-HSA-9839383
- End position
- 160358957
- Start position
- 160343294
- Chromosome
- 1
- Strand
- Forward
- Membrane
- Single-pass type I membrane protein . Cytoplasmic vesicle membrane
- Single-pass type I membrane protein . Melanosome . Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV.
- Cytosol
- PubMed 10993067
- PubMed 25043039
- PubMed 25918421
- PubMed 26280335
- PubMed 26623517
- PubMed 26776682
- PubMed 30598546
- PubMed 30630874
- PubMed 12643545
- PubMed 17081065
- Tissue specificity (tau)
- 0.637903
- Expression inequality (Gini)
- 0.236841
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 123.9
- Ovary
- 75.84
- Thyroid
- 75.3
- Lung
- 70.28
- Nerve - Tibial
- 68.95
Expression in transcripts per million
- Cells - Cultured fibroblasts123.9
- Ovary75.84
- Thyroid75.3
- Lung70.28
- Nerve - Tibial68.95
- Cervix - Endocervix66.59
- Minor Salivary Gland64.55
- Cervix - Ectocervix63.71
- Spleen62.56
- Adipose - Subcutaneous61.02
- Small Intestine - Terminal Ileum60.54
- Uterus60.03
- Fallopian Tube59.14
- Breast - Mammary Tissue59.01
- Artery - Aorta58.32
- Bladder58.22
- Artery - Coronary57.83
- Testis57.18
- Vagina57.09
- Artery - Tibial55.2
- Pituitary54.99
- Adipose - Visceral (Omentum)54.05
- Skin - Sun Exposed (Lower leg)53.45
- Cells - EBV-transformed lymphocytes52.72
- Skin - Not Sun Exposed (Suprapubic)52.07
And 29 more, listed on the interactive page.
- GO:0006509
- GO:0007220
- GO:0016485
- GO:0031293
- GO:0034205
- GO:0042982
- GO:0042987
- GO:0005765
- GO:0005783
- GO:0005794
- GO:0005886
- GO:0005925
- GO:0010008
- GO:0016020
- GO:0030659
- GO:0035577
- GO:0070062
- GO:0070765
- GO:0005515
- GO:0030674
- GO:0051117
- GO:0061133
- GO:0070851
Related records
Trials (117)
- A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
- A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease
- A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
- A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
- A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
- A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
- A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
- A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.
- A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
- A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors
- A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy
- A Study of Semagacestat for Alzheimer's Patients
- A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers
- A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
- A Trial In Patients With Advanced Cancer And Leukemia
- A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation
- Acute Dose-dependent Effects of DMT in Healthy Subjects
Drugs (7)
- Avagacestat Gamma-secretase inhibitor
- Begacestat Gamma-secretase inhibitor
- Nirogacestat Gamma-secretase inhibitor
- Nirogacestat hydrobromide Gamma-secretase inhibitor
- RG-4733 Gamma-secretase inhibitor
- Semagacestat Gamma-secretase inhibitor
- Tarenflurbil Gamma-secretase modulator